TARA ELIZONDO: Open Payments
NPI 1760188502 · LUFKIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$475 in 26 payments from 10 companies in 2025. Trend: 2023 $1,003 · 2024 $554 · 2025 $475
Food & beverage: $475
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 5 | $105 |
| Teva Pharmaceuticals USA, Inc. | 4 | $70 |
| ABBVIE INC. | 4 | $67 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $62 |
| E.R. Squibb & Sons, L.L.C. | 3 | $58 |
| Janssen Pharmaceuticals, Inc | 2 | $35 |
| Lundbeck LLC | 2 | $29 |
| Alkermes, Inc. | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Vanda Pharmaceuticals Inc. | 1 | $14 |
Products named: INGREZZA, VRAYLAR, CAPLYTA, COBENFY, AUSTEDO XR, INVEGA SUSTENNA, UZEDY, ABILIFY ASIMTUFII.
Industry payments across TX — which companies pay providers there.
